Please assess the completion status of the following clinical trial:

Trial Title: Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patients must have a diagnosis of relapsed Waldenstrom's Macroglobulinemia.~In addition to the above, key inclusion and exclusion criteria are listed below.~Inclusion Criteria:~1. At least 18 years of age.~2. Agree to use contraception~3. Hemoglobin ≥ 7.5 g/dL, - Absolute neutrophil count ≥ 1.0 x 109/L (1000/mm3), - Platelets ≥ 50,000/μL~Exclusion Criteria:~1. Is nursing or pregnant~2. Has BMI \> 34.9 kg/m2.~3. Has a positive test for human immunodeficiency virus (HIV-1 or -2) hepatitis C virus (HCV) or hepatitis B surface antigen (HBsAg).~4. Receiving chronic systemic corticosteroid therapy \> 20 mg of prednisone daily.~5. Being treated with other anti-cancer therapies (approved or investigational).~6. Has, at the initiation of study drug, received cytotoxic chemotherapy or a Bruton's tyrosine kinase (BTK)-inhibitor (e.g. ibrutinib) within the past 3 weeks or rituximab within the past 2 months~7. Has an active infection requiring systemic antibiotics.~8. Has had surgery requiring general anesthesia within 4 weeks of starting the study.~9. Has autoimmune cytopenia (anemia, thrombocytopenia, leukopenia).~10. Has heart failure of Class III or IV.~11. Has sensory or motor neuropathy limiting daily activities.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IMO-8400 at escalating dose levels (Type: EXPERIMENTAL): IMO-8400 at escalating dose levels by subcutaneous injection

Based on this trial design, predict the completion outcome and termination type (if applicable).